Individuals with Down syndrome (DS) are at high risk for Alzheimer's disease (AD), yet accessible tools for routine clinical screening of AD in individuals with DS remain limited. Using data from the Alzheimer Biomarker Consortium-Down Syndrome (ABC-DS), we show that integrating plasma pTau217 with performance on the m...
C. Vanderlip, S. Hartley, S. Krinsky-McHale et al.· Annals of Neurology· 0 citations
Depression, anxiety, and higher odds of major cardiometabolic disorders were significantly associated, and IL-6 statistically mediated parts of these associations.
Asma Hallab, S. O'Bryant, Kristine Yaffe et al.· Scientific Reports· 0 citations
Findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms and support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention.
Yue-Xuan Xu, T. I. Gunasekaran, Yian Gu et al.· Lancet Neurology· 1 citation
A DCA Workgroup is developed to develop expert recommendations for implementing supervised, in‐clinic DCAs within US clinical workflows that support recognition, diagnostic evaluation, and care planning across primary and specialty care.
P. Tariot, Darren R. Gitelman, Ishtar Govia et al.· Alzheimer's & Dementia· 0 citations
Higher plasma p-tau217 levels were consistently associated with increased risk of clinical progression and accelerated cognitive decline, and support the potential of p-tau217 for prognostic model development, with direct implications for future trial design.
R. Buckley, D. Townsend, C. Birkenbihl et al.· Journal of the American Medi...· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
